Top Stories
Rentosertib, now in Phase III trials for idiopathic pulmonary fibrosis, showed age-reversal signals that appeared partly independent of improvements in lung function, pointing to potential anti-aging effects beyond its respiratory benefits.
In STEP Young, 40.4% of children aged 6 to <12 years treated with Wegovy were no longer classified as having obesity at week 68, compared with none on placebo.
The premature termination of the HERMES and ATHENA trials due to futility follows the failure of the ZEUS study earlier this year.
SCB-1022 and SCB-1033 generated robust antibody responses and slashed respiratory tract infection rates in older adults.
The company-initiated withdrawal was prompted by the KRAS G12C inhibitor's failure in the confirmatory KRYSTAL-10 trial.
Conference News
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma –– Verekitug also delivered clinically meaningful improvements in lung function (FEV1) ...
Pa-positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatmentOnly one exacerbation meeting the Hill/EMBARC cr...
While cardiologists are paying heed to the discordant results of the Phase III CARDIO-TTRansform study of AstraZeneca and Ionis' Wainua (eplontersen) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), they aren't quite ready to throw the combination therapy baby out with the bathwater.
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, ...
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROI...
